Clinical Trial Update: Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating intrathecal ziconotide for severe refractory neuropathic pain with spinal cord lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain
• Spinal Cord Lesions

Drugs mentioned

• Ziconotide (ziconotide)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Severe Refractory Neuropathic Pain, Spinal Cord Lesions | Phase 3 | Status: UNKNOWN